About century therapeutics inc - IPSC
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
IPSC At a Glance
Century Therapeutics, Inc.
38th Street, 25 North
Philadelphia, Pennsylvania 19104
| Phone | 1-267-817-5790 | Revenue | 109.16M | |
| Industry | Biotechnology | Net Income | -9,580,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 1,556.761% | |
| Fiscal Year-end | 12 / 2026 | Employees | 78 | |
| View SEC Filings |
IPSC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.789 |
| Price to Book Ratio | 0.548 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.064 |
| Enterprise Value to Sales | 0.108 |
| Total Debt to Enterprise Value | 3.705 |
IPSC Efficiency
| Revenue/Employee | 1,399,538.462 |
| Income Per Employee | -122,820.513 |
| Receivables Turnover | 163.664 |
| Total Asset Turnover | 0.378 |
IPSC Liquidity
| Current Ratio | 5.971 |
| Quick Ratio | 5.971 |
| Cash Ratio | 5.83 |
IPSC Profitability
| Gross Margin | 87.999 |
| Operating Margin | -13.777 |
| Pretax Margin | -8.838 |
| Net Margin | -8.776 |
| Return on Assets | -3.321 |
| Return on Equity | -5.982 |
| Return on Total Capital | -4.731 |
| Return on Invested Capital | -4.679 |
IPSC Capital Structure
| Total Debt to Total Equity | 27.41 |
| Total Debt to Total Capital | 21.513 |
| Total Debt to Total Assets | 19.474 |
| Long-Term Debt to Equity | 25.319 |
| Long-Term Debt to Total Capital | 19.872 |